statview j v5 software (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
statview j v5 software
Statview J V5 Software, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statview+j+v5+software/statview+5+0/pm29723866-34-6-10
Average 90 stars, based on 1 article reviews
Statview J V5 Software, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statview+j+v5+software/statview+5+0/pm29723866-34-6-10
Average 90 stars, based on 1 article reviews
statview j v5 software - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Article Snippet: Objectives: The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC).. Methods: One hundred and two patients with advanced HCC were enrolled in this study.. We retrospectively compared patients with fever (more than 38 ° C) within 2 weeks after the start of sorafenib therapy (fever group, n = 34) and patients without fever (non-fever group, n = 68) in terms of survival, best antitumor response, and change in intratumor blood on contrast-enhanced computed tomography (CE-CT) after 2 weeks of sorafenib therapy. Article Title: Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. Article Snippet: Objectives: The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib.. Methods: A total of 103 patients with radiological confirmation of progressive disease (PD) were enrolled.. Results: The median PPS (n = 67) was 6.1 months. |